Loading...
Loading...
NTRBW| Name | Value |
|---|---|
| Revenues | 655.9K |
| Cost of Revenue | 356.3K |
| Gross Profit | 299.7K |
| Operating Expense | 1,123.9K |
| Operating I/L | -824.2K |
| Other Income/Expense | -5.0K |
| Interest Income | 4.2K |
| Pretax | -829.2K |
| Income Tax Expense | 4.2K |
| Net Income/Loss | -829.2K |
Nutriband Inc. specializes in developing transdermal pharmaceutical products, with a focus on an abuse deterrent fentanyl transdermal system for managing chronic pain. The company's primary revenue stream comes from the development and commercialization of its transdermal pharmaceutical products, catering to the needs of clinicians and patients. Additionally, Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices, further expanding its product portfolio and potential revenue streams.
